Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067)...
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First...
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from an interim analysis of CA209-040, a Phase...
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to...
Lilly to Participate in Goldman Sachs Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare...
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have...
Lilly Announces the Early Results of Its Cash Tender Offer
Eli Lilly and Company (NYSE: LLY) announced today that pursuant to its previously announced cash...
PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting
Eli Lilly and Company (NYSE: LLY) announced final results of the Phase III PROCLAIM trial...
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast...
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6...
Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced...
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 1, 2015,...
